Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZymeTx, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Clinical trials evaluating chemiluminescence film-detection, infectious disease platform for influenza testing will enroll 350 patients at three U.S. sites, the firm reports Feb. 13. Point-of-care testing platform developed with strategic partner Polaroid incorporates high-speed film to chemically capture light emissions produced by proprietary molecules and compounds, which release light in the presence of infectious organisms when activated and produced with Polaroid technology. Slated to conclude this spring, trials will be followed by pivotal studies to support FDA clearance
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel